Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices follo...

The Biden administration announced agreements with drug companies to lower the cost of 10 major Medicare medications, potentially saving ta...

The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of ...

The Biden administration has released a list of 10 prescription medicines that will be subject to price negotiations by the U.S. Medicare h...

BI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making,...

Jardiance is the top selling drug of BI in India, used in treatment of type-2 diabetes and for the treatment of heart failure with reduced ...

The drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jard...

German drug maker Boehringer Ingelheim has won approval from the Indian drug regulator to market its top-selling type-2 diabetes medication...

In a statement to ET, BI confirmed it has obtained separate orders granting ad-interim injunction that restrains the two domestic pharmaceu...

Earlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025.

Under its brand Vicra, Dr. Reddy's is expected to sell the drug in India at less than a third of the price charged by Boehringer Ingelheim....

Glenmark launches a drug at almost half the price of those offered by rivals.

While Indian companies still control almost 80% of the market in the country, the strategy of launching specialised patented product is hel...

IMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.

Diabetes estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide.

With Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.